key: cord-0291338-flic8tzc
authors: Peng, Lei; Fang, Zhenhao; Renauer, Paul A.; McNamara, Andrew; Park, Jonathan J.; Lin, Qianqian; Zhou, Xiaoyu; Dong, Matthew B.; Zhu, Biqing; Zhao, Hongyu; Wilen, Craig B.; Chen, Sidi
title: Simultaneous and sequential multi-species coronavirus vaccination
date: 2022-05-08
journal: bioRxiv
DOI: 10.1101/2022.05.07.491038
sha: 17bfa653ac516903e0576a80b8128f3b678f6552
doc_id: 291338
cord_uid: flic8tzc

Although successful COVID-19 vaccines have been developed, multiple pathogenic coronavirus species exist, urging for development of multi-species coronavirus vaccines. Here we developed prototype LNP-mRNA vaccine candidates against SARS-CoV-2 (Delta variant), SARS-CoV and MERS-CoV, and test how multiplexing of these LNP-mRNAs can induce effective immune responses in animal models. A triplex scheme of LNP-mRNA vaccination induced antigen-specific antibody responses against SARS-CoV-2, SARS-CoV and MERS-CoV, with a relatively weaker MERS-CoV response in this setting. Single cell RNA-seq profiled the global systemic immune repertoires and the respective transcriptome signatures of multiplexed vaccinated animals, which revealed a systemic increase in activated B cells, as well as differential gene expression signatures across major adaptive immune cells. Sequential vaccination showed potent antibody responses against all three species, significantly stronger than simultaneous vaccination in mixture. These data demonstrated the feasibility, antibody responses and single cell immune profiles of multi-species coronavirus vaccination. The direct comparison between simultaneous and sequential vaccination offers insights on optimization of vaccination schedules to provide broad and potent antibody immunity against three major pathogenic coronavirus species. One sentence summary Multiplexed mRNA vaccination in simultaneous and sequential modes provide broad and potent immunity against pathogenic coronavirus species.

were introduced in the S2 domain of the respective species (Figure 1a-b) , based on the homologous 125 amino acid positions of SARS-CoV-2, in order to improve expression and stable prefusion state 126 of spikes 23 . The Delta construct ORF encodes the spike of SARS-CoV-2 Delta variant, which has 127 nine mutations (T19R, 156del, 157del, R158G, L452R, T478K, D614G, P681R, and Q1071H) as 128 compared to the original "wildtype" virus (WT, WA-1 or WA1) virus (Figure 1A-B) . To 129 multiplex these constructs, we prepared equal-mass mixture of spike mRNA of Delta, SARS and 130 MERS, which were then encapsulated by lipid nanoparticles on a microfluidics instrument, to 131 generate a triplex LNP-mRNA formulation of vaccine candidate (termed as Triplex-CoV, or 132 Triplex) ( Figure 1C) . We also generated a Delta singlet LNP-mRNA for testing in parallel. The To evaluate the immunogenicity of Delta and Triplex LNP-mRNA vaccines, C57BL/6Ncr (B6) 144 mice were immunized intramuscularly with two doses (prime and boost) of 1µg Delta LNP-145 mRNA, 1 µg or 3 µg (total mRNA mass) Triplex LNP-mRNA, three weeks apart ( Figure 1G ). 146 The peripheral blood mononuclear cells (PBMCs) and plasma were collected two weeks post Figure S3A ). Among the three vaccination groups, only 3µg Triplex LNP-mRNA 154 significantly boosted mice immunity to MERS antigens ( Figure 1H ). As the Delta and Triplex 155 vaccines used the Delta variant as spike antigen, their responses to Delta ELISA antigen were 156 found slightly higher than WT antigen ( Figure 1H) . Despite of the lack of SARS spike antigen in 157 the vaccine, the Delta LNP-mRNA induced antibodies that cross-react with SARS spike, but not 158 MERS spike (Figure 1H) , consistent with the respective degree of homology between these 159 species ( Figure S1 ). The titers are at similarly high level between the 1µg and 3µg Triplex groups 160 for SARS and SARS2 spikes (Figure 1H) , while there is a trend of dose-dependent increase 161 although statistically insignificant ( Figure 1H; Figure S2 ). Compared to those of Triplex 1µg or 162 3µg groups, SARS-binding antibody titer in 1µg Delta LNP-mRNA group was significantly lower. 163 A dose-dependent increase trend of antibody titers was observed for MERS spike in the two 164 Triplex vaccination groups ( Figure 1H ). Considering Delta spike mRNA at the same dose, mice 165 in the 1µg Delta and 3µg Triplex (that also contains 1µg Delta mRNA) groups showed similar 166 titers of antibodies against SARS2 WT and Delta spikes, although an insignificant trend of lower 167 titers was observed in the 3µg Triplex mice ( Figure 1H ; Figure S2 ). Both ECD and RBD ELISA 168 antigen panels showed highly correlated results among four spike types used ( Figure S3B) . In 169 addition, a subset of animals showed relatively higher titer to ECD than RBD ( Figure S3B , off- Figure S7 ). Similar with the results above, the ELISA ECD activity highly correlated with 263 that of RBD ( Figure 5D) . We tested the neutralization activities using pseudovirus assays, which We performed head-to-head sequential vaccination as compared to simultaneous vaccination in 326 mixture, showing that sequential vaccination showed higher antibody responses at the endpoint. Coronavirus spike sequence alignment 353 The spike sequence used to produce the LNP-mRNA vaccines were aligned using Clustal Omega Meta-pathway genes were visualized by heatmap, using log-normalized, scaled expression for GO 565 term genes that were differentially expressed in vaccination groups compared to the PBS control.

Custom R scripts were used for generating various plots. statistical significance was labeled as follows: n.s., not significant; * p < 0.05; ** p < 0.01; *** p 572 < 0.001; **** p < 0.0001. Prism (GraphPad Software) and RStudio were used for these analyses.

Additional information can be found in the supplemental excel tables. Regular experiments were not blinded. NGS data processing were blinded using metadata.

Subsequent analyses were not blinded.

Commercial antibodies were validated by the vendors, and re-validated in house as appropriate.

Custom antibodies were validated by specific antibody -antigen interaction assays, such as ELISA.

Isotype controls were used for antibody validations.

Cell lines were authenticated by original vendors, and re-validated in lab as appropriate.

All cell lines tested negative for mycoplasma. Acknowledgments: 619 We thank various members from Chen and Wilen labs for discussions and support. We thank staffs R TR TQ -----L PP AYTNS F TRGVYYPDK VFRSS VL HS TQD L F L P F FSN VT ---WFH A I H VSGTNGTKR ----FDNP VL P FNDGVYF AS TE -----------PS TS AT I RK I YP AFML GSS VGN FSDGKMGR F FNH T L VL L PDGCGT L L R ---------AF YC I L EPRSGNHCP AGNS YTS F AT YH TP ATDCSDGN YNRN AS L NS FKE YFN L RNC T FMYT YN I TEDE I L -------------KSN VVRGWVFGS TMNNKSQS ---------V I I I NNS TN VV I R ACN FE L CDNP F F AVSKPMGT --------------------------------QTH TM I FDN AFNC T FE Y I SD AFS L D VSEKSGN FK  ------KSN I I RGW I FGT T L DSK TQS ---------L L I VNN ATN VV I K VCE FQFCNDP F L D VYYHKNNK ------------------------------SWMESGVYSS ANNC T FE YVSQP F L MD L EGKQGN FK   -----------EWFG I TQT AQGVH L FSSR YVD L YGG --NMFQF AT L P VYD T I K YYS I I PHS I RS ---I QSDRK AW----AAF YVYK L QP L T F L L D FS VDGY I RR A I DCGFND L SQL HCS YES FD VESGVYS VSS  H L RE F VFKNKDGF L YVYKGYQP I D VVR ----D L PSGFN T L KP I FK L P L G I N I TN FR A I L T AF ------SP AQD TWGTS AAAYF VGYL KP T T FML K YDENGT I TD AVDCSQNP L AE L KCS VKS FE I DKG I YQTSN  N L RE F VFKN I DGYFK I YSKH TP I N L VR ----D L PQGFS AL EP L VD L P I G I N I TR FQT L L AL HRS YL TPGDSSSGWT AGAAAYYVGYL QPR T F L L K YNENGT I TD AVDC AL DP L SE TKC T L KS F T VEKG I 

Coronavirus biology and replication: 878 implications for SARS-CoV-2

Characteristics of SARS-CoV-2 and COVID-19

From SARS and MERS to COVID-19: a brief summary and comparison of severe acute 882 respiratory infections caused by three highly pathogenic human coronaviruses

Zoonotic origins and animal hosts of coronaviruses causing human disease 885 pandemics: A review

Origin and evolution of pathogenic coronaviruses

The Coronaviruses of Animals and 889 Birds: Their Zoonosis, Vaccines, and Models for SARS-CoV and SARS-CoV2. Front Vet Sci 7, 582287

SARS-CoV-2 vaccine 892 protection and deaths among US veterans during 2021

The severe acute respiratory syndrome

Isolation of a novel 897 coronavirus from a man with pneumonia in Saudi Arabia

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and 900 Influenza A Respiratory Viruses

Learning from the past: development of safe and effective COVID-19 vaccines

Coronavirus vaccine development: from SARS and MERS to COVID-19

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike 906 antigen

Safety and immunogenicity of a candidate Middle East respiratory syndrome 908 coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 909 trial

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle 911 Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

Progress of the COVID-19 vaccine 914 effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides 921 Broad Protection in Mice

Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical 923 and subclinical genital herpes

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-925 mediated immunity

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

B cell memory: understanding COVID-19

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence 935 correlate with limited symptom duration

Single-cell landscape of immunological responses in patients with COVID-19

Single-cell multi-omics analysis of the immune response in COVID-19

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction 946 neutralization, microneutralization and pseudotyped virus neutralization assays

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

Comparison of Four SARS-CoV-2 Neutralization Assays. Vaccines (Basel)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 953 Vaccine for Covid-19

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

An interactive web-based dashboard to track COVID-19 in real time

Zoonotic origins of human coronaviruses

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses 963 in mice

Understanding and Manipulating Viral Immunity: Antibody 965

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Waning Immunity after the BNT162b2 Vaccine in Israel

A new bioinformatics analysis tools framework at EMBL-EBI

Jalview Version 2--a multiple 974 sequence alignment editor and analysis workbench

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric 979 viruses

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA 983 Vaccines

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. 985

Spatial reconstruction of single-cell gene 987 expression data

Comprehensive Integration of Single-Cell Data

UMAP: Uniform Manifold Approximation and Projection

It's DE-licious: A Recipe for Differential Expression Analyses of 993 RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR

Bias, robustness and scalability in single-cell differential expression 996 analysis

Co-expression analysis reveals interpretable gene 998 modules controlled by trans-acting genetic variants

Profiler: a web server for functional enrichment analysis and conversions of gene lists 1000 (2019 update)